Prime Stock alert: Moving this pharma stock to a HOLD
Recent announcements relating to ownership change in this pharma stock prompt us to move this stock from a ‘BUY’ to a ‘HOLD’.
Recent announcements relating to ownership change in this pharma stock prompt us to move this stock from a ‘BUY’ to a ‘HOLD’.
A report from Kotak Institutional Equities sparked a bout of selling in mid and small caps. Should you be concerned? Here is what we think.
Results update for 5 of our Prime Stocks.
If you thought you could by-pass mutual funds and dive straight into stock investing, this article will tell you why you still need a MF portfolio.
This commodity stock is well placed to play the changing tide in the sector on account of its affordable valuations.
Consolidation and correction have made stocks of affordable housing finance companies attractive and this is our pick in the space.
results update for 5 of our Prime Stocks
What stock markets should be assessed on, where markets stand now, and other observations.
We are moving an industrial sector stock that we recommended in June 2022, to a HOLD.
We are moving this Prime Stock to a HOLD and this report will explain why.
We think the time is right to partially sell your holdings of this API maker and hold the rest.
In part one of this four-part series we talk about examples of wrong entry into stocks with rich valuations and how to avoid them